Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor
Authors:
- 1 October 2019
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (10) , 1766-1783
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
This publication has 36 references indexed in Scilit:
- Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical ModelsCancer Research, 2015
- Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor2014
- Chronopharmacology and Mechanism of Antitumor Effect of Erlotinib in Lewis Tumor-Bearing MicePLOS ONE, 2014
- Expression of LATS1 contributes to good prognosis and can negatively regulate YAP oncoprotein in non-small-cell lung cancerTumor Biology, 2014
- Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3PLOS ONE, 2013
- Ascertaining an Appropriate Diagnostic Algorithm Using EGFR Mutation-Specific Antibodies to Detect EGFR Status in Non-Small-Cell Lung CancerPLOS ONE, 2013
- A molecular mechanism that links Hippo signalling to the inhibition of Wnt/β‐catenin signallingThe EMBO Journal, 2012
- COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transportBiochemical and Biophysical Research Communications, 2010
- Cytoplasmic/Nuclear Shuttling and Tumor ProgressionAnnals of the New York Academy of Sciences, 2005
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung CancersJNCI: Journal of the National Cancer Institute, 2005